|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
Mechanismenkephalinase inhibitors [+1] |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A 4 week phase 2a, multicentre, randomised, double-blind, placebo-controlled add-on study into safety, tolerability and efficacy of 200 mg t.i.d. of PL37 in patients with peripheral neuropathic pain of diabetic origin treated with pregabalin or gabapentin.
100 Clinical Results associated with Pharmaleads SA
0 Patents (Medical) associated with Pharmaleads SA
100 Deals associated with Pharmaleads SA
100 Translational Medicine associated with Pharmaleads SA